Long-standing gadolinium enhancement in a patient with aquaporin-4-positive myelitis

Abstract

We report the case of a very long-standing spinal cord gadolinium enhancement in a patient with AQP4-positive myelitis, presenting with two clinical relapses while on rituximab. Additional tests conducted to investigate potential differential diagnoses returned negative and the therapy was switched to satralizumab. Follow-up revealed a resolution of symptoms and lesion enhancement. The total duration of lesion enhancement was 14 months. Recognizing the possibility of long-lasting enhancement in AQP4-positive myelitis is crucial for diagnostic accuracy. Moreover, it may indicate subclinical disease activity, and might suggest the need for close magnetic resonance imaging (MRI) monitoring and an adjustment in therapeutic strategy.

Keywords

MRI neuromyelitis optica spectrum disorder (NMOSD)aquaporin-4 (AQP4) antibodies longitudinal extensive transverse myelitis (LETM)gadolinium enhancement

Get full access to this article

View all access options for this article.

References

Wingerchuk

Banwell

Bennett

, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189.

Kümpfel

Giglhuber

Aktas

, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)–revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol 2024; 271: 141–176.

Molazadeh

Filippatou

Vasileiou

, et al. Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. J Neuroimmunol 2021; 360: 577702.

Jarius

Aktas

Ayzenberg

, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol 2023; 270(7): 3341–3368.

Katz

Taubenberger

Cannella

, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34(5): 661–669.

Lerch

Schanda

Lafon

, et al. More efficient complement activation by anti–aquaporin-4 compared with anti–myelin oligodendrocyte glycoprotein antibodies. Neurol Neuroimmunol Neuroinflammation 2022; 10: e200059.

Dubey

Pittock

Krecke

, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019; 76: 301–309.

Shah

Morris

Buciuc

, et al. Frequency of asymptomatic optic nerve enhancement in a large retrospective cohort of patients with aquaporin-4+ NMOSD. Neurology 2022; 99: e851–e857.

Ren

, et al. Persistently gadolinium-enhancing lesion is a predictor of poor prognosis in NMOSD attack: A clinical trial. Neurotherapeutics 2021; 18(2): 868–877.

10.

Barreras

Vasileiou

Filippatou

, et al. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology 2022; 99: e2504–e2516.